On April 1, 2020, the FDA issued a notice on its official website requesting that all ranitidine products be withdrawn from the market because the unacceptable dose of impurities N-nitrosodimethylamine (N-nitrosodimethylamine) was detected in some drugs. , Referred to as NDMA)
NDMA
NDMA is classified as a category 2A carcinogen. It is a substance that may cause cancer in humans. It is quickly absorbed through the digestive tract and respiratory tract and slowly absorbed through the skin, mainly causing liver damage. Usually people may also consume low levels of NDMA through the diet, but low levels will not increase the risk of cancer. But sustained high intake levels may increase the risk of cancer, such as chronic diseases requiring long-term use of drugs.
The investigation found that even under normal storage conditions, the NDMA content of ranitidine products will increase. And as the temperature rises, the NDMA content will increase significantly, and as the storage time increases, the NDMA content will also increase.
Ranitidine
Ranitidine, also known as furanidamine, is a potent histamine H2 receptor antagonist, which can effectively inhibit gastric acid secretion caused by stimulation of histamine, pentagastrin and carbachol, and reduce gastric acid Stomach enzyme activity.
Ranitidine can be used clinically to treat duodenal ulcers, gastric ulcers, reflux esophagitis, and other diseases that cause excessive gastric acid secretion.
At present, there is still no conclusion as to whether ranitidine products containing NDMA as impurities are harmful to the human body, and the evaluation should still be in progress.
If you are concerned about the safety of ranitidine, you can consider the use of famotidine, cimetidine, omeprazole, omeprazole, lansoprazole and other drugs. .
